European Case Law Identifier: | ECLI:EP:BA:2009:T146907.20090203 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 03 February 2009 | ||||||||
Case number: | T 1469/07 | ||||||||
Application number: | 97944240.7 | ||||||||
IPC class: | A61K 9/20 | ||||||||
Language of proceedings: | EN | ||||||||
Distribution: | C | ||||||||
Download and more information: |
|
||||||||
Title of application: | Pharmaceutical compositions for sustained release of the HMG-CoA reductase inhibitor fluvastatin | ||||||||
Applicant name: | NOVARTIS AG, et al | ||||||||
Opponent name: | Ratiopharm GmbH Actavis UK Ltd Actavis GmbH |
||||||||
Board: | 3.3.02 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Remittal - yes: fresh case | ||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t071469eu1.html
Date retrieved: 17 May 2021